Fluphenazine (oral) versus atypical antipsychotics for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 7, 2016, Pages

  Sampford, James R ^a   Sampson, Stephanie ^b   Li, Bao Guo ^c   Zhao, Sai ^d   Xia, Jun ^b   Furtado, Vivek A ^e  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d Systematic Review Solutions Ltd   (China)

^e UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; FLUPHENAZINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; SULPIRIDE; SULTOPRIDE;

AKATHISIA; AKINESIA; ANTICHOLINERGIC EFFECT; ANXIETY; BRIEF PSYCHIATRIC RATING SCALE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DATA BASE; DRUG SAFETY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL DISEASE; HOSPITAL ADMISSION; HOSTILITY; HUMAN; MENTAL HEALTH; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PATIENT SATISFACTION; POSITIVE SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RELAPSE; REVIEW; SCHIZOPHRENIA; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; META ANALYSIS; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FLUPHENAZINE; HUMANS; QUETIAPINE FUMARATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SCHIZOPHRENIA; SULPIRIDE; TREATMENT OUTCOME;

EID: 84977619276     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010832.pub2     Document Type: Review

References (95)

1. Boyer P. Efficacy of low doses of atypical neuroleptics (benzamides) in defect states [Etude de l'efficacite de faibles doses de neuroleptiques atypiques (benzamides) dans les etats deficitaires]. Annales Medico-Psychologiques 1986;144(6):593-9. [MEDLINE: 2880542]
2. Boyer P, Puech AJ. Determinants for clinical activity of neuroleptic drugs: chemical substances, doses, assessment tools. Psychiatrie and Psychobiologie 1987;2(4):296-305.
3. Pichot P, Boyer P. A double blind, controlled, multicenter trial of low dose amisulpride (solian (R) 50) versus low dose fluphenazine in the treatment of negative symptoms in chronic schizophrenia [Essai multicentrique controle, en double insu, amisulpride (solian (r) 50) contre fluphenazine a faibles doses dans le traitement du syndrome deficitaire des schizophrenies chroniques]. Annales de Psychiatrie 1988;3(3):312-20.
4. Pichot P, Boyer P. Controlled double-blind multi-centre trial of low dose amisulpride versus fluphenazine in the treatment of the negative syndrome of chronic schizophrenia. In: Borenstein P, et al. editor(s). Amisulpride. Paris: Expansion Scientifique Française, 1989:125-38.
5. Conley RR. New antipsychotic strategies: quetiapine and risperidone vs. fluphenazine in treatment resistant schizophrenia. Http://www.clinicaltrials.gov 2005.
6. Conley RR, Kelly DL, Nelson MW, Richardson CM, Feldman S, Benham R, et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Schizophrenia Bulletin 2005;31(4):163-8.
7. Kelly D Conley RR. Sexual side effects of quetiapine and risperidone compared with fluphenazine. Psychoneuroendocrinology 1999.
8. Kelly DL, Conley RR. A randomised double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology 2006;31(3):340-6.
9. Kelly DL, Conley RR. Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. Journal of Clinical Psychiatry 2005;66(1):80-4.
10. Dossenbach M, Friedel P, Jakovljevic M, Hotujac L, Folnegovic V, Uglesic B, et al. Olanzapine versus fluphenazine - six weeks treatment of acute schizophrenia. 10th European Colleague of Neuropsychopharmacology Congress; 1997 September 13-17; Vienna. 1997.
11. Dossenbach M, Jakovljevic M, Folnegovi V, Uglesic B, Dodig G, Friedel P, et al. Olanzapine versus fluphenazine - six weeks of treatment of anxiety symptoms during acute schizophrenia. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria. 1998, issue 1-2:203.
12. Dossenbach MRK, Folnegovic-Smalc V, Hotujac L, Uglesic B, Tollefson GD, Grundy SL, et al. Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2004;28(2):311-8.
13. Jakovljevic M, Dossenbach MR, Friedel P, Schausberger B, Grundy SL, Hotujac L, et al. Olanzapine versus fluphenazine in the acute (six week) treatment of schizophrenia. Psychiatria Danubina 1999; Vol. 11, issue 1-2:3-11.
14. Jakovljevic M, Dossenbach MRK. Olanzapine versus fluphenazine in the acute (six week) treatment of schizophrenia. Psychiatria Danubina 1999; Vol. 11, issue 1-2:3-10.
15. Jakovljevic M, Pivac N, Mihaljevic-Peles A, Mustapic M, Relja M, Ljubicic D, et al. The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study. Progress in Neuro-psychopharmacology & Biological Psychiatry 2007;31(2):399-402.
16. Saletu B, Kufferle B, Grunberger J, Foldes P, Topitz A, Anderer P. Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine. Neuropsychobiology 1994;29(3):125-35.
17. Boyer P. Efficacy of low doses of atypical neuroleptics (benzamides) in defect states [Etude de l'efficacite de faibles doses de neuroleptiques atypiques (benzamides) dans les etats deficitaires]. Annales Medico-Psychologiques 1986;144(6):593-9. [MEDLINE: 2880542]
18. Boyer P, Lecrubier Y, Puech AJ. Treatment of positive and negative symptoms: pharmacologic approaches. Modern Problems of PharmacoPsychiatry 1990;24:152-74. [MEDLINE: 1970852]
19. Pichot P, Boyer P. A controlled double-blind multi-centre trial of high dose amisulpride versus haloperidol in acute psychotic states. Amisulpride. Paris: Expansion Scientifique Francaise, 1989:83-92. [MEDLINE: ]
20. Pichot P, Boyer P. A double blind, controlled, multicenter trial of amisulpride versus high dose haloperidol in acute psychotic disorders. Annales de Psychiatrie 1988, issue 3:326-32.
21. Boyer P. Amisulpride in the treatment of negative schizophrenic symptoms: results of a double-blind controlled trial versus placebo. Amisulpride. Paris: Expansion Scientifique Française, 1989:111-23. [MEDLINE: ]
22. Boyer P, Lecrubier Y, Puech AJ. Treatment of positive and negative symptoms: pharmacologic approaches. Modern Problems of PharmacoPsychiatry 1990;24:152-74. [MEDLINE: 1970852]
23. Boyer P, Puech A, Kossmann L, Lecrubier Y, Dewailly J. A controlled study versus placebo with low dose of amisulpride in the treatment of the purely deficit schizophrenia [Etude controlee versus placebo de faibles doses d'amisulpride dans le traitement des formes purement deficitaires de schizophrenie.]. L'Encephale 1989;15(2):300. [MEDLINE: ]
24. Boyer P, Puech AJ, Lecrubier Y. Double blind trial versus placebo of low dose amisulpride (Solian 50) in schizophrenia with exclusively negative symptoms. Preliminary analysis of results [Etude en double insu contre placebo de l'amisulpride (Solian (r) 50) a faible dose chez des schizophrenes purement deficitaires. Premiere analyse des resultats]. Annales de Psychiatrie 1988;3(3):321-5. [MEDLINE: ]
25. Lecrubier Y, Puech AJ, Aubin F, Boyer P, Deyrieux B. Improvement by amisulpride of the negative syndrome in non-psychotic subjects: a preliminary study. Psychiatrie and Psychobiologie 1988;3(5):329-34. [MEDLINE: 3618275]
26. Boyer P, Turjanski S, Fleurot O. Amisulpride in the treatment of acute schizophrenia: a double-blind comparison with haloperidol. Proceedings of the 20th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1996 Jun 23-27; Melbourne, Australia. 1996. [MEDLINE: ]
27. Möller HJ, Boyer P, Fleurot O, Rein W. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. Psychopharmacology 1997;132(4):396-401. [MEDLINE: 9298518]
28. Möller HJ, Boyer P, Rein W, Eich FX. Treatment of schizophrenic patients with actue exacerbations: a double-blind comparison of amisulpride and haloperidol. PharmacoPsychiatry 1997;30:199. [MEDLINE: ]
29. Möller HJ, Boyer P, Turjanski S, Fleurot O. Amisulpride in the treatment of subchronic or chronic schizophrenia with acute exacerbation: a double-blind comparison with haloperidol. Proceedings of the 8th Congress of the Association of European Psychiatrists; 1996 Jul 7-12; London, UK. 1996. [MEDLINE: ]
30. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Archives of General Psychiatry 1992; Vol. 49, issue 5:345-53.
31. Ravanic DB, Djukic-Dejanovic SM, Stojiljkovic M, Jankovic S, Paunovic VR, Bankovic D. Antipsychotic efficacy of clozapine vs fluphenazine in positive and negative schizophrenia syndrome. Journal of Neural Transmission 1996; Vol. 103:Xlvi.
32. Djukic-Dejanovic SM, Pantovic MM, Alexopulos C, Milovanovic DR, Paunovic VR, Ravanic DB. Clozapine vs. classical antipsychotics in schizophrenia. Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan. 2002.
33. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
34. Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Archives of General Psychiatry 1982;39(7):784-8.
35. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry 2004;161(Suppl 2):1-56.
36. Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
37. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices, 3: comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: Comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
38. Cost-Effectiveness Analysis Registry (CEA). https://research.tufts-nemc.org/cear4/ accessed 11/09/13.
39. Darling HF. Fluphenazine: a preliminary study. Disease of the Nervous System 1959;20(4):167-70.
40. Davies LM, Lewis S, Jones PB, Barnes TRE, Gaughran F, Hayhurst K, et al. Cost-effectiveness of first- vs. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. British Journal of Psychiatry 2007;191(JULY):14-22. [EMBASE: 2007328135; MEDLINE: 17602120]
41. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
42. Dencker SJ, Johansson R, Malm U. Pharmacokinetic and pharmacodynamic studies on high doses of fluphenazine. Psychopharmacology (Berl) 1988;94(2):237-41.
43. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
44. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
45. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313(3 August):275-83.
46. Dysken MW, Javaid JI, Chang SS, Schaffer C, Shahid A, Davis JM. Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology (Berl) 1981;73(3):205-10.
47. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
48. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
49. Essali A, Al-Haj HN, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD000059.pub2; CD000059]
50. Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria. International Journal of Technology Assessment in Health Care 2005;21(2 Spring):240-5.
51. Fleischhacker WW, Bergmann KJ, Perovich R, Pestreich LK, Borenstein M, Lieberman JA, et al. The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia. Psychopharmacological Bulletin 1989;25(2):222-6.
52. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
53. Gebhardt R, Pietzcker A, Strauss A, Stoeckel M, Langer C, Freudenthal K. Scale formation in the AMDP-system [Skalenbildung im AMDP-System]. Archives of Psychiatry and Neurological Sciences 1983;233:223-45.
54. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991;41(1):1-24.
55. Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
56. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health. DHEW Publication NO (ADM), 1976:124-585.
57. Guy E. Abnormal Involuntary Movement Scale. Rockville, MD, National Institute of Mental Health, U.S. Department of Health and Human Services: ECDEU Assessment Manual for Psychopharmacology 1976.
58. Healy D, Le Noury J, Harris M, Butt M, Linden S, Whitaker C, et al. Mortality in schizophrenia and related psychoses: data from two cohorts, 1875-1924 and 1994-2010. BMJ Open 2012;2(5):e001810. [DOI: 10.1136/bmjopen-2012-001810]
59. Health Economic Evaluation Database (HEED). Online ISBN: 9780470510933. [DOI: 10.1002/9780470510933]
60. Hospital Episode Statistics, Admitted Patient Care - England 2011-12: Main Specialties (.xls). http://www.hscic.gov.uk/searchcatalogue?productid=9161&q=title%3a%22hospital+episode+statistics%22&sort=Relevance&size=10&page=1#top (accessed May 2013) 2011-12.
61. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
62. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
63. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychological Medicine 1983;13:177-83.
64. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
65. Jones PB, Barnes TRE, Davies L. Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia - cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Archives of General Psychiatry 2006;63:1079-86.
66. Kane JM, Woerner M, Sarantakos S. Depot neuroleptics: a comparison review of standard, intermediate and low-dose regimens. Journal of Clinical Psychiatry 1986;47(Suppl 5):30-3.
67. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
68. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13:261-76.
69. Kendall T. The rise and fall of the atypical antipsychotics. British Journal of Psychiatry 2011;199:266-8.
70. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
71. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
72. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373(9657):31-41.
73. Lieberman JA, Stroup TS, McEvoy JP. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209-23.
74. Maayan N, Quraishi Seema N, David A, Jayaswal A, Eisenbruch M, Rathbone J, et al. Fluphenazine decanoate (depot) and enanthate for schizophrenia. Cochrane Database of Systematic Reviews 2015, Issue 2. [DOI: 10.1002/14651858.CD000307.pub2; CD000307]
75. Maier W, Buller R, Philipp M, Heuser I. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. Journal of Affective Disorders 1988;14(1):61-8. [DOI: 10.1016/0165-0327(88)90072-9]
76. Mangalore R, Knapp M. Cost of schizophrenia in England. Journal of Mental Health Policy and Economics 2007;10(1):23-41.
77. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
78. Marvaha S, Johnson S. Schizophrenia and employment - a review. Social Psychiatry and Psychiatric Epidemiology 2004;39:337-49.
79. Matar HE, Almerie MQ, Sampson S. Fluphenazine (oral) versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD006352.pub2; CD006352]
80. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiological Review 2008;30:67-76.
81. Millar J. A trial of fluphenazine in schizophrenia. British Journal of Psychiatry 1963;109:428-32.
82. National Institute for Health and Clinical Excellence. The Epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care (Pharmacological Update of Clinical Guideline 20). NCGC National Clinical Guideline Centre 2012:1-636.
83. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799-812.
84. Parrott AC, Hindmarch I. The Leeds sleep evaluation questionnaire in psychopharmacological investigations - a review. Psychopharmacology 1980;71:173-9.
85. Compiled by Lesley Curtis. Unit costs of health and social care 2012. http://www.pssru.ac.uk/project-pages/unit-costs/2012/ (accessed May 2013) 2012:47.
86. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Medicine 2005;2(5):e141. [DOI: 10.1371/journal.pmed.0020141]
87. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
88. Seeman P. Atypical antipsychotics: mechanism of action. Canadian Journal of Psychiatry 2002;47(1):27-38.
89. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandanavica 1970;212:S11-19.
90. Tardy M, Huhn M, Engel Rolf R, Leucht S. Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 8. [DOI: 10.1002/14651858.CD009230.pub2; CD009230]
91. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
92. van Os J, Rutten BPF, Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophrenia Bulletin 2008;34(6):1066-82.
93. Essential Medicines: WHO model list. http://whqlibdoc.who.int/hq/2005/a87017_eng.pdf March 2005; Vol. 14th edition.
94. Williams, A (editor). Health economics: the cheerful face of dismal science?. Health and Economics. London (UK): Macmillan, 1987.
95. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.